“Innovation has received various FDA designations, reinforcing the potential of the company’s pipeline, while also providing better odds of a drug candidate's expedited approval, often with added exclusivity protections. Almost three-in-four drugs (73%) approved by the FDA in the U.S. in 2016 received some form of expedited development and review, with one-in-three (36%) representing first-in-class status."

http://www.ipharminc.com/special-fda-designations/

1. Brilacidin-OM - Fast Track

2. Brilacidin-ABSSSI - QIDP (first-in-class)

3. Prurisol - 505(b)(2)

4. Kevetrin - Orphan Drug